| Identification | Back Directory | [Name]
TD-165 | [CAS]
2305936-56-3 | [Synonyms]
TD-165
(2S,4R)-1-((2S)-2-(11-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)undecanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide | [Molecular Formula]
C46H59N7O8S | [MDL Number]
MFCD33029328 | [Molecular Weight]
870.07 |
| Chemical Properties | Back Directory | [Boiling point ]
1096.3±65.0 °C(Predicted) | [density ]
1.292±0.06 g/cm3(Predicted) | [solubility ]
DMSO : 50 mg/mL (57.47 mM; Need ultrasonic) | [form ]
Solid | [pka]
10.75±0.40(Predicted) | [color ]
White to yellow |
| Hazard Information | Back Directory | [Biological Activity]
TD-165 is a PROTAC-based cereblon (CRBN) degrader. TD-165 comprises a cereblon (CRBN) ligand binding group, a linker and an von Hippel-Landau (VHL) binding group[1].
TD-165 (0-100 nM; 24 hours) shows 50% degradation concentration (DC50) and maximum degradation (Dmax) value of 20.4 nM and 99.6%, respectively[1].TD-165 (0.1-10 μM; 24 hours) leads to a concentration-dependent decrease in the level of CRBN proteins in HEK293T cells[1]. | [References]
[1]. Kim K, et al. Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera.Sci Rep. 2019 Dec 23;9(1):19654. |
|
|